JP2006514013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514013A5 JP2006514013A5 JP2004555563A JP2004555563A JP2006514013A5 JP 2006514013 A5 JP2006514013 A5 JP 2006514013A5 JP 2004555563 A JP2004555563 A JP 2004555563A JP 2004555563 A JP2004555563 A JP 2004555563A JP 2006514013 A5 JP2006514013 A5 JP 2006514013A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- alkyl
- group
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- -1 1,2-diphenylethyl Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 0 *C(C(N*)=O)N(*)C(*)=O Chemical compound *C(C(N*)=O)N(*)C(*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42833202P | 2002-11-21 | 2002-11-21 | |
| US60/428,332 | 2002-11-21 | ||
| PCT/US2003/037318 WO2004047825A1 (en) | 2002-11-21 | 2003-11-21 | Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010210237A Division JP2010280725A (ja) | 2002-11-21 | 2010-09-17 | 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514013A JP2006514013A (ja) | 2006-04-27 |
| JP2006514013A5 true JP2006514013A5 (enExample) | 2007-01-11 |
| JP4928079B2 JP4928079B2 (ja) | 2012-05-09 |
Family
ID=32393386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004555563A Expired - Fee Related JP4928079B2 (ja) | 2002-11-21 | 2003-11-21 | 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 |
| JP2010210237A Withdrawn JP2010280725A (ja) | 2002-11-21 | 2010-09-17 | 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010210237A Withdrawn JP2010280725A (ja) | 2002-11-21 | 2010-09-17 | 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7687530B2 (enExample) |
| EP (1) | EP1567138B1 (enExample) |
| JP (2) | JP4928079B2 (enExample) |
| AT (1) | ATE493980T1 (enExample) |
| AU (1) | AU2003291134A1 (enExample) |
| DE (1) | DE60335652D1 (enExample) |
| ES (1) | ES2363914T3 (enExample) |
| PT (1) | PT1567138E (enExample) |
| WO (1) | WO2004047825A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2408408C (en) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
| AU2003291143A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| DE60335652D1 (de) * | 2002-11-21 | 2011-02-17 | Genzyme Corp | Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung |
| CA2957704A1 (en) | 2004-01-21 | 2005-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| EP2604703B1 (en) * | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
| USRE46843E1 (en) | 2005-03-14 | 2018-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for evaluating graft survival in a solid organ transplant recipient |
| US20110201519A1 (en) * | 2008-08-18 | 2011-08-18 | Sarwal Minnie M | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject |
| US9938579B2 (en) | 2009-01-15 | 2018-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarker panel for diagnosis and prediction of graft rejection |
| US9290813B2 (en) | 2009-12-02 | 2016-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| CA2794255C (en) | 2010-03-25 | 2020-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Protein and gene biomarkers for rejection of organ transplants |
| WO2012139051A2 (en) | 2011-04-06 | 2012-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Autoantibody biomarkers for iga nephropathy |
| EP2827861A4 (en) * | 2012-03-19 | 2016-03-16 | Aposignal Bioscience Llc | COMPOSITION AND METHODS FOR CELLULAR MODULATION |
| WO2017142879A1 (en) | 2016-02-16 | 2017-08-24 | The Regents Of The University Of California | Methods for immune system modulation with microporous annealed particle gels |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4944796A (en) * | 1988-11-14 | 1990-07-31 | Ici Americas Inc. | Certain 2-(disubstituted amino) acetanilide herbicides |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
| US6420374B1 (en) * | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
| US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| AU5152293A (en) | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| DE4430127A1 (de) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
| DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| AU3993795A (en) * | 1994-12-02 | 1996-06-19 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| FR2730411B1 (fr) * | 1995-02-14 | 1997-03-28 | Centre Nat Rech Scient | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
| US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| DE69532557T2 (de) | 1995-07-20 | 2004-12-23 | Cellena (Cell Engineering) Ag | Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene |
| IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
| DE69620639T2 (de) * | 1995-11-22 | 2002-10-17 | Darwin Discovery Ltd., Cambridge | Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6211160B1 (en) * | 1996-09-06 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| ATE247974T1 (de) * | 1996-12-06 | 2003-09-15 | Amgen Inc | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
| US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| WO1998039026A2 (en) | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
| US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
| US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
| US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| US6229878B1 (en) * | 1998-01-21 | 2001-05-08 | Lucent Technologies, Inc. | Telephone answering method and apparatus |
| US6359061B1 (en) * | 1999-03-19 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Amide compound libraries |
| EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| WO2001034649A2 (en) | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| CA2408408C (en) * | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
| CN1239485C (zh) * | 2000-05-22 | 2006-02-01 | 里奥制药有限公司 | 作为IL－1β和TNF－α抑制剂的二苯酮类 |
| AU2003280429A1 (en) * | 2002-06-26 | 2004-01-19 | The Trustees Of Columbia Uninersity In The City Of New York | Use of streptavidin to inhibit transplant rejection |
| AU2003291143A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| DE60335652D1 (de) * | 2002-11-21 | 2011-02-17 | Genzyme Corp | Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung |
-
2003
- 2003-11-21 DE DE60335652T patent/DE60335652D1/de not_active Expired - Lifetime
- 2003-11-21 AT AT03783726T patent/ATE493980T1/de not_active IP Right Cessation
- 2003-11-21 PT PT03783726T patent/PT1567138E/pt unknown
- 2003-11-21 ES ES03783726T patent/ES2363914T3/es not_active Expired - Lifetime
- 2003-11-21 WO PCT/US2003/037318 patent/WO2004047825A1/en not_active Ceased
- 2003-11-21 AU AU2003291134A patent/AU2003291134A1/en not_active Abandoned
- 2003-11-21 EP EP03783726A patent/EP1567138B1/en not_active Expired - Lifetime
- 2003-11-21 JP JP2004555563A patent/JP4928079B2/ja not_active Expired - Fee Related
- 2003-11-21 US US10/719,055 patent/US7687530B2/en not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,157 patent/US20100256211A1/en not_active Abandoned
- 2010-09-17 JP JP2010210237A patent/JP2010280725A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538873A5 (enExample) | ||
| JP2004511518A5 (enExample) | ||
| JP2005501120A5 (enExample) | ||
| JP2009545611A5 (enExample) | ||
| JP2014530240A5 (enExample) | ||
| JP2001526276A5 (enExample) | ||
| KR940005566A (ko) | 퀴놀린 화합물 | |
| JP2007504161A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2006511484A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| JP2011500544A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2007517035A5 (enExample) | ||
| JP2004537564A5 (enExample) | ||
| JP2008508214A (ja) | 女性の性障害の治療用ピペラジン誘導体 | |
| JP2008513439A5 (enExample) | ||
| JP2003525279A5 (enExample) | ||
| JP2006522813A5 (enExample) | ||
| RU2005113168A (ru) | Производные 2-пиридона в качестве ингибитора нейтрофильной эластазы | |
| JP2013507425A5 (enExample) | ||
| JP2007516205A5 (enExample) | ||
| JP2002527414A5 (enExample) | ||
| JP2012530758A5 (enExample) | ||
| RU97107457A (ru) | Производное азола |